NCT05925530
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05925530 |
| Title | Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE) |
| Acronym | MDT-BRIDGE |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | SWE | ITA | HUN | FRA | ESP | DEU | CZE | CAN | AUT |
CKB BOOST